Archives of Disease in Childhood - Fetal and Neonatal Edition最新文献

{"title":"Congenital syphilis.","authors":"Ana Hercberg, Elena Gomez Fernandez, Carmen Gomez Gerez, María Luisa Lorente, Irene Cuadrado, Sara Guillen","doi":"10.1136/archdischild-2026-330678","DOIUrl":"https://doi.org/10.1136/archdischild-2026-330678","url":null,"abstract":"","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between cerebral proton magnetic resonance spectroscopy and school-age neurodevelopment after perinatal asphyxia and therapeutic hypothermia: a cohort study.","authors":"Lorea Vicente Elcano, Mathies Rondagh, Andrea van Steenis, Bregje O van Oldenmark, Johannes P Toirkens, Floris Groenendaal, Linda S de Vries, Sylke J Steggerda","doi":"10.1136/archdischild-2026-330796","DOIUrl":"https://doi.org/10.1136/archdischild-2026-330796","url":null,"abstract":"<p><strong>Objective: </strong>To assess the association of early proton magnetic resonance spectroscopy (¹H-MRS) metabolite ratios with adverse outcomes at 5-8 years in infants with hypoxic-ischaemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH) and to compare the association with outcome at 5-8 years versus outcome at 2 years.</p><p><strong>Design, setting and patients: </strong>Single-centre, retrospective cohort study of 91 infants with moderate to severe HIE undergoing TH between 2011 and 2020, ¹H-MRS performed between day 4 and 6 after birth and outcome at 5-8 years. The subgroup with both 2-year and 5-year to 8-year outcomes (n=81) was used for comparative analyses. Adverse outcome at 5-8 years was defined as death or moderate-severe disability (total intelligence quotient score <85, Movement Assessment Battery for Children II <15th percentile, cerebral palsy and severe sensory impairment).</p><p><strong>Results: </strong>Among 91 infants, 49 (54%) had adverse outcomes at 5-8 years, including 20 who died. The lactate/N-acetylaspartate (Lac/NAA) peak-area ratio was the strongest predictor of adverse outcome at school age (area under the curve (AUC) of 0.90 and OR 1.11 per 0.01 increase (95% CI 1.05 to 1.16)).The predictive performance of neonatal ¹H-MRS was slightly higher at 2 years, with Lac/NAA AUC 0.93 (OR 1.11, 95% CI 1.05 to 1.16) versus 0.89 (OR 1.09, 95% CI 1.04 to 1.15) at 5-8 years, with comparable effect sizes indicating preserved long-term association.</p><p><strong>Conclusions: </strong>Neonatal ¹H-MRS biomarkers, especially Lac/NAA peak-area ratio, were associated with adverse outcomes at school age. Including ¹H-MRS in routine neonatal imaging could improve prognostication and guide early interventions.</p>","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neonatal automated oxygen titration algorithms: response characteristics and performance.","authors":"Hylke H Salverda, Christoph E Schwarz, Andrew P Marshall, Zeke P Hausmann, Timothy J Gale, Christian F Poets, Nelson Claure, Tom G Goos, Helmut D Hummler, Charles C Roehr, Tomasz Szczapa, Arjan B Te Pas, Peter A Dargaville","doi":"10.1136/archdischild-2026-330785","DOIUrl":"https://doi.org/10.1136/archdischild-2026-330785","url":null,"abstract":"<p><strong>Objective: </strong>Neonatal respiratory support devices now have algorithms for automated adjustment of oxygen concentration (fraction of inspired oxygen (FiO₂)) in response to oxygen saturation (SpO₂) disturbances, but their performance has not been systematically examined. We investigated the response of six available devices and algorithms to standardised and simulated SpO₂ disturbances.</p><p><strong>Design: </strong>Bench-top study in neonatal centres.</p><p><strong>Methods: </strong>Devices under study received SpO₂ input from a vital signs simulator at 1 Hz; device response was recorded as measured FiO₂ in the respiratory circuit. Response to protracted hypoxaemia (SpO₂=80%) and hyperoxaemia (SpO₂=98%) was examined in several test conditions. In closed-loop testing, measured FiO₂ was combined with abstracted patient data in an oxygenation simulator, generating novel SpO₂ values input to the device. Device capability in keeping simulated SpO₂ in target range (91-95%) was examined, as was FiO₂ adjustment frequency and propensity for FiO₂ oscillation.</p><p><strong>Results: </strong>The FiO₂ trajectories in response to SpO₂ disturbances differed considerably between devices. Maximum rate of sustained FiO₂ escalation (ΔFiO₂/min) during hypoxaemia was Avea: 0.30; Fabian: 0.20; Leoni: 0.20; SLE: 0.10; Sophie: 0.062; Vapotherm: 0.30. Corresponding values for FiO₂ reduction during hyperoxaemia were 1.20, 0.20, 0.20, 0.13, 0.53 and 1.32. In closed-loop testing, average SpO₂ target range time proportion was 51%, 52%, 55%, 77%, 64% and 53% for the six devices, respectively, with 1.9-5.1 automated FiO₂ adjustments/min, in some cases with a prominent oscillatory pattern.</p><p><strong>Conclusions: </strong>Automated oxygen control devices exhibit considerable variation in their FiO₂ response to SpO₂ disturbances, with important consequences for SpO₂ targeting potential and the pattern of FiO₂ adjustment.</p>","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Child's daily life at 10 years following moderate, late preterm, or early term birth: results from EPIPAGE-2 and ELFE cohorts.","authors":"Laura Pavicic, Laetitia Marchand-Martin, Ayoub Mitha, Véronique Pierrat, Valérie Benhammou, Jean-Baptiste Muller, Mélissa Arneton, Pierre-Yves Ancel, Marie-Aline Charles","doi":"10.1136/archdischild-2026-330570","DOIUrl":"https://doi.org/10.1136/archdischild-2026-330570","url":null,"abstract":"<p><strong>Introduction: </strong>Preterm birth includes four subgroups: extremely (<28 weeks' gestation), very (28⁺⁰-31⁺⁶), moderate (32⁺⁰-33⁺⁶, MPT) and late (34⁺⁰-36⁺⁶, LPT). While school attainment is well-studied across subgroups, other aspects of daily life are rarely reported for MPT, LPT and early term (37⁺⁰-38⁺⁶, ET) or are explored only qualitatively.</p><p><strong>Objective: </strong>Assess daily life, including school and quality of life at age 10 years for MPT, LPT and ET compared with full-term (39⁺⁰-40⁺⁶, FT) peers.</p><p><strong>Methods: </strong>Children born in 2011 from two birth cohorts (ELFE: ≥33⁺⁰ weeks; EPIPAGE-2: ≤34⁺⁶ weeks) completed a 10-year follow-up via telephone interview (n=8373) and home visit (n=6418). Weighting addressed selection bias. Outcome-wide regressions (modified Poisson, linear) were used to calculate adjusted relative risks (aRR) and beta-coefficients (β).</p><p><strong>Results: </strong>MPT had a higher risk of receiving any school support (aRR 1.67, 95% CI 1.10 to 2.54). Their risk for difficulties in French and mathematics was, respectively, 1.32 (95% CI 1.01 to 1.74) and 1.50 (95% CI 1.13 to 1.99) times higher, while school-related quality of life was 0.30 (95% CI -0.58 to -0.02) SD lower relative to FT. They were 2.02 times more likely to be non-swimmers (95% CI 1.24 to 3.29). Both MPT/LPT were less likely to eat school meals but reported higher overall well-being scores (+0.16 SD and +0.13 SD, respectively). The study sample may under-represent socioeconomically deprived groups.</p><p><strong>Conclusions: </strong>MPT/LPT children's daily lives differ from those of FT children in some respects. Those discrepancies should be explored further to better understand needs and accommodate them. Findings may not generalise to disadvantaged groups.</p>","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enteral docosahexaenoic and arachidonic acid supplementation and retinopathy of prematurity: a reanalysis of randomised controlled trials in preterm infants.","authors":"Ulrika Sjöbom, Aldina Pivodic, Pia Lundgren, Sissel J Moltu, Brandy Frost, Daniel T Robinson, Christine Henriksen, Ann Hellstrom, Anders K Nilsson","doi":"10.1136/archdischild-2026-331134","DOIUrl":"https://doi.org/10.1136/archdischild-2026-331134","url":null,"abstract":"","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bloodstream infections in young infants: a cohort study.","authors":"Anna A M Gibbs, Kevin B Laupland, Felicity Edwards, Samuel Channon-Wells, David Harley, Kathleen Falster, David L Paterson, Patrick N A Harris, Helen G Liley, Adam D Irwin","doi":"10.1136/archdischild-2025-329824","DOIUrl":"https://doi.org/10.1136/archdischild-2025-329824","url":null,"abstract":"<p><strong>Objective: </strong>The burden of bloodstream infection (BSI) is highest among infants. We aim to describe temporal trends in the incidence and characteristics of BSI in young infants.</p><p><strong>Design: </strong>Birth cohort study.</p><p><strong>Setting: </strong>Queensland, Australia.</p><p><strong>Patients: </strong>All <90-day-old infants with culture-confirmed BSI detected by Pathology Queensland from 2000 to 2019.</p><p><strong>Main outcome measures: </strong>The annual incidence of BSI was calculated using live births in public hospitals. Infections were categorised as early onset (0≤3 days) or late onset (4<90 days). Comorbidities were defined using a paediatric complex chronic conditions classification system. Temporal trends were examined using time series models.</p><p><strong>Results: </strong>In total, 2327 incident BSIs occurred in 2173 infants. Late-onset BSI comprised 67% (n=1568). Comorbidities were present in 25% (n=188) of early-onset and 48% (n=716) of late-onset BSI. Common pathogens were <i>Escherichia coli</i> (21%, n=501), Group B Streptococcus (GBS) (21%, n=493) and <i>Staphylococcus aureus</i> (14%, n=338). Overall incidence was 2.98 per 1000 live births (early-onset 1.01, late-onset 1.96), which increased over time (incidence rate ratio 1.01 (95% CI 1.00 to 1.01)). The incidence of Enterobacterales BSI increased by 1.96% each year (1.02 (1.01 to 1.03)) and GBS by 1.91% (1.02 (1.01, 1.04)). Early-onset GBS increased by 11% per year from 2014 to 2019 (1.11 (1.04 to 1.19)). The overall case fatality rate was 8.8% (early onset 6.4%, late onset 10%).</p><p><strong>Conclusions: </strong>The incidence of GBS and Enterobacterales BSI has risen in young infants in Queensland, especially for early-onset GBS since 2014. These findings highlight the increasing importance of Enterobacterales infections in young infants and the need to reconsider prevention strategies for early-onset GBS.</p>","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannula with long and narrow tubing versus short binasal prongs for nasal intermittent positive pressure ventilation in preterm infants with respiratory distress syndrome: a randomised non-inferiority trial.","authors":"Sikha Sharma, Adil Ahmed Khan, Pradeep Debata, Anita Yadav, Jogender Kumar","doi":"10.1136/archdischild-2026-330607","DOIUrl":"https://doi.org/10.1136/archdischild-2026-330607","url":null,"abstract":"<p><strong>Objectives: </strong>To determine whether nasal intermittent positive pressure ventilation (NIPPV) delivered via a cannula with long and narrow tubing (CLNT) was non-inferior to short binasal prongs (SBP) in preventing treatment failure among preterm infants with respiratory distress syndrome (RDS).</p><p><strong>Design: </strong>Open-label, non-inferiority randomised controlled trial.</p><p><strong>Setting: </strong>Level III neonatal unit.</p><p><strong>Patients: </strong>Preterm infants (<34 weeks' gestation) requiring primary NIPPV support within 6 hours of birth for RDS.</p><p><strong>Interventions: </strong>Infants were randomly assigned (1:1) to receive NIPPV via CLNT or SBP.</p><p><strong>Main outcome measures: </strong>The primary outcome was NIPPV failure requiring intubation within 72 hours of randomisation. The prespecified non-inferiority margin was an absolute risk difference of 10%. Secondary outcomes included nasal trauma, mortality and major neonatal morbidities.</p><p><strong>Results: </strong>A total of 316 infants were randomised (158 per group). NIPPV failure occurred in 27 (17.1%) infants in the CLNT group and 23 (14.6%) in the SBP group (risk difference: 2.5%, 95% CI -5.51 to 10.56). Because the upper bound of the 95% CI exceeded the prespecified non-inferiority margin, non-inferiority was not demonstrated. Mortality, bronchopulmonary dysplasia, severe intraventricular haemorrhage, retinopathy of prematurity and duration of respiratory support were similar between groups. Nasal trauma was significantly lower with CLNT (any grade: 12.0% vs 44.9%, RR 0.27, 95% CI 0.17 to 0.42; moderate-to-severe: 4.4% vs 21.5%, RR 0.21, 95% CI 0.09 to 0.45).</p><p><strong>Conclusions: </strong>CLNT did not demonstrate non-inferiority to SBP according to the prespecified non-inferiority criterion for preventing treatment failure. Nevertheless, CLNT was associated with substantially lower rates of nasal trauma without evidence of increased short-term morbidity or mortality.</p><p><strong>Registration number: </strong>Clinical Trial Registry of India (CTRI/2022/09/045914).</p>","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paediatric outcomes after maternal nipocalimab for haemolytic disease of the fetus and newborn: an open-label, single-arm study.","authors":"Derek P de Winter, Kenneth J Moise, Leona E Ling, Dick Oepkes, Eleonor Tiblad, E J T Joanne Verweij, John Smoleniec, Ulrich J Sachs, Gregor Bein, Mark D Kilby, Russell S Miller, Roland Devlieger, Anne Debeer, Jocelyn H Leu, Robert M Nelson, Valerie Smith, Lisa B Schwartz, May Lee Tjoa, Yosuke Komatsu, Shumyla Saeed-Khawaja, Enrico Lopriore","doi":"10.1136/archdischild-2026-331009","DOIUrl":"https://doi.org/10.1136/archdischild-2026-331009","url":null,"abstract":"<p><strong>Objectives: </strong>To describe haemolytic disease outcomes, growth, neurodevelopment and health-related quality of life (HRQoL) through 24 months of life in infants exposed to nipocalimab in pregnancies at high risk of early-onset severe haemolytic disease of the fetus and newborn (EOS-HDFN).</p><p><strong>Design: </strong>A multicentre, open-label, single-arm trial.</p><p><strong>Setting: </strong>Centres with expertise in HDFN management.</p><p><strong>Patients: </strong>Pregnant individuals with previous EOS-HDFN and maternal anti-D titres ≥32 or anti-K titres ≥4.</p><p><strong>Interventions: </strong>Weekly nipocalimab (30 and/or 45 mg/kg) from 14 to 35 gestational weeks.</p><p><strong>Main outcome measures: </strong>Infants' cord-blood alloantibody titres at birth, HDFN management, growth through 6 months, neurodevelopment (caregiver-reported Ages and Stages Questionnaire, third edition (ASQ-3)) and HRQoL assessments through 24 months of life.</p><p><strong>Results: </strong>Of 13 pregnancies, 12 resulted in live births; one fetal loss occurred due to intrauterine transfusion (IUT) complications. A single simple transfusion was administered in one of seven infants delivered after a maternal nipocalimab course without IUTs, where cord blood alloantibody titres were <8. Multiple transfusions (one to seven simple transfusions/infant; one exchange transfusion) were administered to five infants delivered after early nipocalimab discontinuation and IUTs, with cord-blood alloantibody titres ranging from 512 to 32 768. No unusual growth patterns were observed through 6 months. No neurodevelopmental delays were identified through 24 months of life, with mean ASQ-3 domain scores within normal ranges. HRQoL outcomes were positive across physical, emotional, social and cognitive functioning.</p><p><strong>Conclusions: </strong>Maternal nipocalimab in pregnancies at high risk of EOS-HDFN may reduce adverse neonatal outcomes correlating with low cord-blood alloantibody titres, without affecting growth through 6 months, neurodevelopment or HRQoL through 24 months of life.</p><p><strong>Trial registration number: </strong>NCT03842189.</p>","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148904889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurodevelopmental impairment and morbidity patterns across two epochs among extremely preterm infant survivors in Australia and New Zealand.","authors":"Temesgen Getaneh, Nusrat Homaira, Abrar Chughtai, Trisha Parmar, Elizabeth Maria Hurrion, Georgina Chambers, Alice Rumbold, Kei Lui","doi":"10.1136/archdischild-2025-330101","DOIUrl":"https://doi.org/10.1136/archdischild-2025-330101","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate neurodevelopmental outcomes at 2-3 years of age among survivors of extremely preterm infant (EPI).</p><p><strong>Design and setting: </strong>Analysis of prospectively collected Australian and New Zealand Neonatal Network data on infants born <28 weeks' gestation between 2010 and 2019.</p><p><strong>Main outcome: </strong>The prevalence of neurodevelopmental impairment (NDI), defined as any moderate to severe cerebral palsy (CP), sensory impairment or developmental delay (score <70) at 2-3 years of age was determined. Epoch comparisons (2010-204 vs 2015-2019) and the impact of major morbidity on NDI were examined, adjusting for maternal age, antenatal steroids, gestational age, Apgar score, admission temperature, sex and breast milk feeding.</p><p><strong>Results: </strong>Of 6617 EPIs, 15.5% had NDI. Developmental delay was most prevalent (14.5%), including language (11.1%), motor (5.9%), cognitive (5.7%) domains, followed by CP (3.2%), deafness (1.4%) and blindness (0.4%). Compared with infants without morbidity, adjusted odds of NDI increased with one (adjusted OR (aOR) 1.50, 95% CI 1.21 to 1.84), two (aOR 2.09, 95% CI 1.60 to 2.53) and three or more coexisting morbidities (aOR 3.56, 95% CI 2.73 to 4.65). Between epochs, bronchopulmonary dysplasia increased by 6.9% and retinopathy of prematurity by 3.8%, alongside a rise in developmental delay (10.3% to 17.8%), contributing to a 6.6% absolute increase in NDI. Survivors born at 22-23 weeks had the highest NDI rates, increasing from 23.0% to 26.4%.</p><p><strong>Conclusion: </strong>NDI rates among EPI increased over time and were associated with increasing multiple morbidities. Although changes in EPIs survival patterns may have contributed to these trends, reducing neonatal morbidities and strengthening neuroprotective care remain priorities.</p>","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of brewers' yeast or beta-glucan derived from <i>Saccharomyces cerevisiae</i> on breast milk supply following preterm birth: the BLOOM randomised controlled trial.","authors":"Luke Grzeskowiak, Lauren Williams, Alice Rumbold, Bronni Simpson, Renee L Kam, Lisa Nicole Yelland, Kathryn Dansie, Wendy V Ingman, Amy Keir, Kathryn A Martinello, Lisa H Amir","doi":"10.1136/archdischild-2025-330214","DOIUrl":"https://doi.org/10.1136/archdischild-2025-330214","url":null,"abstract":"<p><strong>Objective: </strong>Breast milk is the optimal source of nutrition for preterm infants; however, low breast milk production is common following a preterm birth. This study aimed to determine if taking brewers' yeast or beta-glucan improves daily expressed breast milk volume.</p><p><strong>Design: </strong>Randomised, blinded, parallel, placebo-controlled trial.</p><p><strong>Setting: </strong>Three Australian tertiary-level neonatal units.</p><p><strong>Patients: </strong>Mothers with a singleton or twin pregnancy who gave birth at <34 weeks' gestation.</p><p><strong>Interventions: </strong>Mothers were randomised within 72 hours of birth into three parallel groups in a 1:1:1 ratio to receive either brewers' yeast, beta-glucan or placebo capsules for 7 days.</p><p><strong>Main outcome measure: </strong>Total expressed breast milk volume over a 24-hour period on day 7 of intervention.</p><p><strong>Results: </strong>A total of 105 mothers underwent randomisation between August 2022 and April 2024 (36 brewers' yeast, 35 beta-glucan and 34 placebo). The adjusted mean difference in daily expressed breast milk volume was 94 mL/day (95% CI -51 mL/day to 239 mL/day) between the brewers' yeast and placebo groups and -25 mL/day (95% CI -173 mL/day to 123 mL/day) between the beta-glucan and placebo groups. Maternal side effects were similar across groups.</p><p><strong>Conclusion: </strong>We found no clear effect of short-term administration of brewers' yeast or beta-glucan on breast-milk production following preterm birth; both interventions were well tolerated. Given the small sample size, these findings do not rule out the possibility of a clinically meaningful benefit of brewers' yeast and suggest further research with a larger sample size may be warranted to clarify the potential clinical impact.</p><p><strong>Trial registration number: </strong>ACTRN12622000968774.</p>","PeriodicalId":8177,"journal":{"name":"Archives of Disease in Childhood - Fetal and Neonatal Edition","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}